journal
MENU ▼
Read by QxMD icon Read
search

Lancet HIV

journal
https://www.readbyqxmd.com/read/28919303/acquisition-of-wild-type-hiv-1-infection-in-a-patient-on-pre-exposure-prophylaxis-with-high-intracellular-concentrations-of-tenofovir-diphosphate-a-case-report
#1
Elske Hoornenborg, Maria Prins, Roel C A Achterbergh, Lycke R Woittiez, Marion Cornelissen, Suzanne Jurriaans, Neeltje A Kootstra, Peter L Anderson, Peter Reiss, Henry J C de Vries, Jan M Prins, Godelieve J de Bree
BACKGROUND: Pre-exposure prophylaxis (PrEP) with emtricitabine and tenofovir disoproxil fumarate is highly effective against acquisition of HIV infection, and only two cases of infection with a multidrug-resistant virus have been reported under adequate long-term adherence, as evidenced by tenofovir diphosphate concentrations in dried blood spots. We report a case of wild-type HIV-1 infection despite consistent use of emtricitabine and tenofovir disoproxil fumarate. METHODS: The patient participated in the Amsterdam PrEP project, a demonstration project of daily and event-driven PrEP...
September 14, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28918878/raltegravir-becomes-a-once-daily-antiretroviral
#2
François Raffi, Clotilde Allavena
No abstract text is available yet for this article.
September 11, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28918877/raltegravir-1200-mg-once-daily-versus-raltegravir-400-mg-twice-daily-with-tenofovir-disoproxil-fumarate-and-emtricitabine-for-previously-untreated-hiv-1-infection-a-randomised-double-blind-parallel-group-phase-3-non-inferiority-trial
#3
Pedro Cahn, Richard Kaplan, Paul E Sax, Kathleen Squires, Jean-Michel Molina, Anchalee Avihingsanon, Winai Ratanasuwan, Evelyn Rojas, Mohammed Rassool, Mark Bloch, Linos Vandekerckhove, Peter Ruane, Yazdan Yazdanpanah, Christine Katlama, Xia Xu, Anthony Rodgers, Lilly East, Larissa Wenning, Sandy Rawlins, Brenda Homony, Peter Sklar, Bach-Yen Nguyen, Randi Leavitt, Hedy Teppler
BACKGROUND: Once daily regimens are preferred for HIV-1 treatment, to facilitate adherence and improve quality of life. We compared a new once daily formulation of raltegravir to the currently marketed twice daily formulation. METHODS: In this randomised, double-blind, parallel-group, phase 3, non-inferiority study, we enrolled participants aged 18 years or older with HIV-1 RNA of 1000 or more copies per mL and no previous antiretroviral treatment at 139 sites worldwide...
September 11, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28867268/control-of-hiv-epidemic-improve-access-to-testing-and-art
#4
Sten H Vermund
No abstract text is available yet for this article.
August 31, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28867267/testing-and-linkage-to-hiv-care-in-china-a-cluster-randomised-trial
#5
Zunyou Wu, Zhenzhu Tang, Yurong Mao, Paul Van Veldhuisen, Walter Ling, David Liu, Zhiyong Shen, Roger Detels, Guanghua Lan, Lynda Erinoff, Robert Lindblad, Diane Gu, Houlin Tang, Lian Hu, Qiuying Zhu, Li Lu, Neal Oden, Albert L Hasson, Yan Zhao, Jennifer M McGoogan, Xianmin Ge, Nanci Zhang, Keming Rou, Jinhui Zhu, Hui Wei, Cynthia X Shi, Xia Jin, Jian Li, Julio S G Montaner
BACKGROUND: Multistage, stepwise HIV testing and treatment procedures can result in lost opportunities to provide timely antiretroviral therapy (ART). Incomplete engagement of patients along the care cascade translates into high preventable mortality. We aimed to identify whether a structural intervention to streamline testing and linkage to HIV health care would improve testing completeness, ART initiation, and viral suppression and reduce mortality. METHODS: We did a cluster-randomised, controlled trial in 12 hospitals in Guangxi, China...
August 31, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28843988/the-amagugu-intervention-for-disclosure-of-maternal-hiv-to-uninfected-primary-school-aged-children-in-south-africa-a-randomised-controlled-trial
#6
Tamsen J Rochat, Alan Stein, Mario Cortina-Borja, Frank Tanser, Ruth M Bland
BACKGROUND: Increasing populations of children who are HIV-exposed but uninfected will face the challenge of disclosure of parental HIV infection status. We aimed to test the efficacy of an intervention to increase maternal HIV-disclosure to primary school-aged HIV-uninfected children. METHODS: This randomised controlled trial was done at the Africa Health Research Institute in KwaZulu-Natal, South Africa. Women who had tested HIV positive at least 6 months prior, had initiated HIV treatment or been enrolled in pretreatment HIV care, and had an HIV-uninfected child (aged 6-10 years) were randomly allocated to either the Amagugu intervention or enhanced standard of care, using a computerised algorithm based on simple randomisation and equal probabilities of being assigned to each group...
August 23, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28843987/integrating-disclosure-support-into-family-hiv-care
#7
Lucie Cluver, Lorraine Sherr
No abstract text is available yet for this article.
August 23, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28803889/cancer-risk-in-people-living-with-hiv
#8
Nancy A Hessol, Howard D Strickler
No abstract text is available yet for this article.
August 10, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28803888/cancer-risk-in-hiv-infected-people-in-the-usa-from-1996-to-2012-a-population-based-registry-linkage-study
#9
Raúl U Hernández-Ramírez, Meredith S Shiels, Robert Dubrow, Eric A Engels
BACKGROUND: Monitoring cancer risk among HIV-infected people in the modern antiretroviral therapy (ART) era is essential given their elevated risk for many cancers and prolonged survival with immunosuppression, ART exposure, and ageing. We aimed to examine cancer risk in HIV-infected people in the USA as compared with that in the general population. METHODS: We did a registry-linkage study with data from population-based HIV and cancer registries in the USA (the HIV/AIDS Cancer Match Study)...
August 10, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28801191/household-survey-of-hiv-incidence-in-rwanda-a-national-observational-cohort-study
#10
Sabin Nsanzimana, Eric Remera, Steve Kanters, Augustin Mulindabigwi, Amitabh B Suthar, Jean Paul Uwizihiwe, Mutagoma Mwumvaneza, Edward J Mills, Heiner C Bucher
BACKGROUND: In Rwanda, HIV prevalence among adults aged 15-49 years has been stable at 3% since 2005. The aim of this study was to characterise HIV incidence across Rwanda. METHODS: We did a nationally representative, prospective HIV incidence survey for the period of 2013-14, which used two-stage sampling. We randomly selected 492 villages in the first sampling stage and 14 households per village in the second stage. Participants completed a questionnaire and 14 140 people were tested for HIV...
August 8, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28801190/how-will-we-get-there-how-will-we-know
#11
Jeffrey W Eaton, James Hargreaves
No abstract text is available yet for this article.
August 8, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28784426/comparative-efficacy-and-safety-of-second-line-antiretroviral-therapy-for-treatment-of-hiv-aids-a-systematic-review-and-network-meta-analysis
#12
Steve Kanters, Maria Eugenia Socias, Nicholas I Paton, Marco Vitoria, Meg Doherty, Dieter Ayers, Evan Popoff, Keith Chan, David A Cooper, Matthew O Wiens, Alexandra Calmy, Nathan Ford, Sabin Nsanzimana, Edward J Mills
BACKGROUND: Selection of optimal second-line antiretroviral therapy (ART) has important clinical and programmatic implications. To inform the 2016 revision of the WHO ART guidelines, we assessed the comparative effectiveness and safety of available second-line ART regimens for adults and adolescents in whom first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimens have failed. METHODS: In this systematic review and network meta-analysis, we searched for randomised controlled trials and prospective and retrospective cohort studies that evaluated outcomes in treatment-experienced adults living with HIV who switched ART regimen after failure of a WHO-recommended first-line NNRTI-based regimen...
August 4, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28784425/second-line-antiretroviral-therapy-so-much-to-be-done
#13
Yibeltal Assefa, Charles F Gilks
No abstract text is available yet for this article.
August 4, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28779855/progress-of-unaids-90-90-90-targets-in-a-district-in-kwazulu-natal-south-africa-with-high-hiv-burden-in-the-hipss-study-a-household-based-complex-multilevel-community-survey
#14
Anneke Grobler, Cherie Cawood, David Khanyile, Adrian Puren, Ayesha B M Kharsany
BACKGROUND: With the goal of eliminating new HIV infections, UNAIDS set the ambitious 90-90-90 targets to be achieved by 2020. We assessed whether these targets are being met among participants of the HIV Incidence Provincial Surveillance System (HIPSS) in a high-burden district of South Africa. METHODS: We used data from a HIPSS household-based, cross-sectional survey of HIV prevalence and incidence done in the uMgungundlovu district, KwaZulu-Natal, in 2014 and 2015...
August 2, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28779854/men-and-the-young-are-key-to-reaching-the-first-90
#15
Kholoud Porter, Annabelle Gourlay
No abstract text is available yet for this article.
August 2, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28768605/cost-effectiveness-of-early-identification-of-hiv-infection
#16
Brooke E Nichols, Gesine Meyer-Rath
No abstract text is available yet for this article.
July 28, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28768604/cost-effectiveness-of-screening-for-hiv-in-primary-care-a-health-economics-modelling-analysis
#17
Rebecca F Baggaley, Michael A Irvine, Werner Leber, Valentina Cambiano, Jose Figueroa, Heather McMullen, Jane Anderson, Andreia C Santos, Fern Terris-Prestholt, Alec Miners, T Déirdre Hollingsworth, Chris J Griffiths
BACKGROUND: Early HIV diagnosis reduces morbidity, mortality, the probability of onward transmission, and their associated costs, but might increase cost because of earlier initiation of antiretroviral treatment (ART). We investigated this trade-off by estimating the cost-effectiveness of HIV screening in primary care. METHODS: We modelled the effect of the four-times higher diagnosis rate observed in the intervention arm of the RHIVA2 randomised controlled trial done in Hackney, London (UK), a borough with high HIV prevalence (≥0·2% adult prevalence)...
July 28, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28732774/vaginal-dysbiosis-and-pre-exposure-prophylaxis-efficacy
#18
Janneke van de Wijgert, Sheena McCormack
No abstract text is available yet for this article.
July 18, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28732773/efficacy-of-oral-pre-exposure-prophylaxis-prep-for-hiv-among-women-with-abnormal-vaginal-microbiota-a-post-hoc-analysis-of-the-randomised-placebo-controlled-partners-prep-study
#19
Renee Heffron, R Scott McClelland, Jennifer E Balkus, Connie Celum, Craig R Cohen, Nelly Mugo, Elizabeth Bukusi, Deborah Donnell, Jairam Lingappa, James Kiarie, Tina Fiedler, Matthew Munch, David N Fredricks, Jared M Baeten
BACKGROUND: Daily oral tenofovir-based pre-exposure prophylaxis (PrEP) is high efficacious for HIV prevention among women with high adherence. However, the effect of abnormal vaginal microbiota on PrEP efficacy is of concern. We investigated whether bacterial vaginosis modified the efficacy of oral PrEP. METHODS: We used prospectively collected data from women in the Partners PrEP Study, a placebo-controlled trial of daily oral PrEP (either tenofovir monotherapy or a combination of tenofovir and emtricitabine) in HIV serodiscordant couples aged 18 years or older in Kenya and Uganda that showed high efficacy in women...
July 18, 2017: Lancet HIV
https://www.readbyqxmd.com/read/28729158/fixed-dose-combination-dolutegravir-abacavir-and-lamivudine-versus-ritonavir-boosted-atazanavir-plus-tenofovir-disoproxil-fumarate-and-emtricitabine-in-previously-untreated-women-with-hiv-1-infection-aria-week-48-results-from-a-randomised-open-label-non-inferiority
#20
Catherine Orrell, Debbie P Hagins, Elena Belonosova, Norma Porteiro, Sharon Walmsley, Vicenç Falcó, Choy Y Man, Alicia Aylott, Ann M Buchanan, Brian Wynne, Cindy Vavro, Michael Aboud, Kimberly Y Smith
BACKGROUND: Dolutegravir is a once-daily integrase strand transfer inhibitor with no need for pharmacokinetic boosting that is approved for the treatment of HIV-1 infection. Because women are often under-represented in HIV clinical trials, we addressed the safety and efficacy of dolutegravir in women with HIV-1. METHODS: The ARIA study is a randomised, open-label, multicentre, active-controlled, parallel-group, non-inferiority phase 3b study done in 86 hospital and university infectious disease clinics, local health clinics, and private infectious disease clinics in 12 countries and one US territory, in North America, South America, Europe, Africa, and Asia...
July 17, 2017: Lancet HIV
journal
journal
49635
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"